Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1975 Oct;37(10):1059-63.
doi: 10.1136/hrt.37.10.1059.

Factors predisposing to postural hypotensive symptoms in the treatment of high blood pressure

Factors predisposing to postural hypotensive symptoms in the treatment of high blood pressure

S Talbot et al. Br Heart J. 1975 Oct.

Abstract

Symptoms due to orthostatic and exertional hypotension occurred in 23-4 per cent of 448 hypertensive patients treated with guanethidine, debrisoquine, or bethanidine. Symptoms were significantly more frequent in patients treated with guanethidine than in those treated with bethanidine or debrisoquine. Women rather than men and patients with radiological evidence of cardiomegaly, electrocardiographic evidence of left ventricular hypertrophy, or ST/T wave changes, developed these symptoms significantly more often than other patients. A raised blood urea was found more frequently in patients with postural hypotensive symptoms. Characteristically guanethidine produced early morning postural hypotensive symptoms, wheras hypotensive symptoms caused by bethanidine and debrisoquine occurred at other times of the day and particularly one to two hours after tablet ingestion. Debrisoquine and guanethidine had a significantly greater negative chronotropic effect than bethanidine. It is suggested that negative chronotropic effects of these drugs may potentiate hypotensive symptoms in patients with cardiovascular, renal, or cerebrovascular disease. It should be possible to minimize symptoms of postural hypotension by attention to predisposing factors and selection of treatment accordingly.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Pharmacol Exp Ther. 1958 Dec;124(4):324-32 - PubMed
    1. Circ Res. 1962 Jan;10:83-8 - PubMed
    1. Clin Sci. 1963 Aug;25:107-14 - PubMed
    1. J Clin Invest. 1962 Nov;41(11):1981-7 - PubMed
    1. Br Med J. 1967 Dec 2;4(5578):519-21 - PubMed

MeSH terms

LinkOut - more resources